{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T03:33:14Z","timestamp":1773718394447,"version":"3.50.1"},"reference-count":71,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>\u201cBasal-like\u201d (BL) morphology and the expression of cancer testis antigens (CTA) in breast cancer still have unclear prognostic significance. The aim of our research was to explore correlations of the morphological characteristics and tumor microenvironment in triple-negative breast carcinomas (TNBCs) with multi-MAGE-A CTA expression and to determine their prognostic significance. Clinical records of breast cancer patients who underwent surgery between January 2017 and December 2018 in four major Croatian clinical centers were analyzed. A total of 97 non-metastatic TNBCs with available tissue samples and treatment information were identified. Cancer tissue sections were additionally stained with programmed death-ligand 1 (PD-L1) Ventana (SP142) and multi-MAGE-A (mAb 57B). BL morphology was detected in 47 (49%) TNBCs and was associated with a higher Ki-67 proliferation index and histologic grade. Expression of multi-MAGE-A was observed in 77 (79%) TNBCs and was significantly associated with BL morphology. Lymphocyte-predominant breast cancer (LPBC) status was detected in 11 cases (11.3%) and significantly correlated with the Ki-67 proliferation index, increased number of intratumoral lymphocytes (itTIL), and PD-L1 expression. No impact of BL morphology, multi-MAGE-A expression, histologic type, or LPBC status on disease-free survival was observed. Our data suggest that tumor morphology could help identify patients with potential benefits from CTA-targeting immunotherapy.<\/jats:p>","DOI":"10.3390\/ijms25084513","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T07:44:09Z","timestamp":1713771849000},"page":"4513","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic Value of \u201cBasal-like\u201d Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer"],"prefix":"10.3390","volume":"25","author":[{"given":"Toni","family":"\u010ceprnja","sequence":"first","affiliation":[{"name":"Department of Pathology, Forensic Medicine and Cytology, University Hospital of Split, 21000 Split, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snje\u017eana","family":"Tomi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathology, Forensic Medicine and Cytology, University Hospital of Split, 21000 Split, Croatia"},{"name":"Department of Pathology, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melita","family":"Peri\u0107 Balja","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Center \u201cSestre Milosrdnice\u201d, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zlatko","family":"Maru\u0161i\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zagreb University Hospital Center, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerija","family":"Bla\u017ei\u0107evi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Osijek, 31000 Osijek, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio Cesare","family":"Spagnoli","sequence":"additional","affiliation":[{"name":"CNR Institute \u201cTranslational Pharmacology\u201d, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-9708","authenticated-orcid":false,"given":"Antonio","family":"Jureti\u0107","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospital Dubrava, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesna","family":"\u010capkun","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital of Split, 21000 Split, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Te\u010di\u0107","family":"Vuger","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospital \u201cSestre Milosrdnice\u201d, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1517-720X","authenticated-orcid":false,"given":"Zenon","family":"Pogoreli\u0107","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, University Hospital of Split, 21000 Split, Croatia"},{"name":"Department of Surgery, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Mrkli\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathology, Forensic Medicine and Cytology, University Hospital of Split, 21000 Split, Croatia"},{"name":"Department of Pathology, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1677\/erc.1.00758","article-title":"Stable portrait of breast tumors during progression: Data from biology, pathology, and genetics","volume":"11","author":"Lacroix","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/bcr1636","article-title":"Basal-like grade III invasive ductal carcinoma of the breast: Patterns of metastasis and long-term survival","volume":"9","author":"Fulford","year":"2007","journal-title":"Breast Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/01.pas.0000213306.05811.b9","article-title":"Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5\/6, and overexpress HER2 or EGFR","volume":"30","author":"Hicks","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","article-title":"Breast cancer molecular subtypes respond differently to preoperative chemotherapy","volume":"11","author":"Rouzier","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/path.4280","article-title":"Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes","volume":"232","author":"Lehmann","year":"2014","journal-title":"J. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/modpathol.2012.244","article-title":"Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry, and transcriptional profiles","volume":"26","author":"Gazinska","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/modpathol.2009.145","article-title":"Triple-negative breast cancer: Clinicopathological characteristics and relationship with basal-like breast cancer","volume":"23","author":"Thike","year":"2010","journal-title":"Mod. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2007.13.1748","article-title":"Basal-like breast cancer: A critical review","volume":"26","author":"Rakha","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/modpathol.3800528","article-title":"Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma","volume":"19","author":"Livasy","year":"2006","journal-title":"Mod. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5858\/134.1.130","article-title":"Basal-like breast carcinoma: A phenotypically distinct entity","volume":"134","author":"Haupt","year":"2010","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/jcp.2006.041731","article-title":"Demystifying basal-like breast carcinomas","volume":"60","author":"Clarke","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/modpathol.3800255","article-title":"Estrogen receptor-negative breast carcinomas: A review of morphology and immunophenotypical analysis","volume":"18","author":"Putti","year":"2005","journal-title":"Mod. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/biohorizons\/hzn007","article-title":"Morphological and immunophenotypic analysis of basal-like carcinoma of the breast","volume":"1","author":"Winter","year":"2008","journal-title":"Biosci. Horiz."},{"key":"ref_20","unstructured":"Lokuhetty, D., White, V.A., Watanabe, R., and Cree, I.A. (2019). WHO Classification of Tumors, Breast Tumours, IARC. [15th ed.]."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cserni, G., Quinn, C.M., Foschini, M.P., Bianchi, S., Callagy, G., Chmielik, E., Decker, T., Fend, F., Kov\u00e1cs, A., and van Diest, P.J. (2021). Triple-negative breast cancer histological subtypes with a favourable prognosis. Cancers, 13.","DOI":"10.3390\/cancers13225694"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41523-021-00362-1","article-title":"Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer","volume":"8","author":"Loi","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00262-017-2072-1","article-title":"Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy","volume":"67","author":"Balatoni","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"57386","DOI":"10.18632\/oncotarget.18065","article-title":"Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A meta-analysis","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-10-1","article-title":"The immune score as a new possible approach for the classification of cancer","volume":"10","author":"Galon","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s13277-012-0411-6","article-title":"The prognostic significance of tumor-associated stroma in invasive breast carcinoma","volume":"33","author":"Ahn","year":"2012","journal-title":"Tumor Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without Carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_30","first-page":"1","article-title":"The cancer\/testis genes: Review, standardization, and commentary","volume":"4","author":"Scanlan","year":"2004","journal-title":"Cancer Immun."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"\u010ceprnja, T., Mrkli\u0107, I., Peri\u0107 Balja, M., Maru\u0161i\u0107, Z., Bla\u017ei\u0107evi\u0107, V., Spagnoli, G.C., Jureti\u0107, A., \u010capkun, V., Te\u010di\u0107 Vuger, A., and Vrdoljak, E. (2022). Prognostic significance of lymphocyte infiltrate localization in triple-negative breast cancer. J. Pers. Med., 12.","DOI":"10.3390\/jpm12060941"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/annonc\/mdq325","article-title":"Cancer\u2013testis antigen expression in triple-negative breast cancer","volume":"22","author":"Curigliano","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ademuyiwa, F.O., Bshara, W., Attwood, K., Morrison, C., Edge, S.B., Karpf, A.R., James, S.A., Ambrosone, C.B., O\u2019Connor, T.L., and Levine, E.G. (2012). NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS ONE, 7.","DOI":"10.1371\/annotation\/5cdf6105-2a52-497a-86b3-db8f4a4e439c"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.acthis.2014.01.003","article-title":"Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas","volume":"116","author":"Spagnoli","year":"2014","journal-title":"Acta Histochem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2011.06.025","article-title":"Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation","volume":"48","author":"Karn","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.breast.2018.08.106","article-title":"Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?","volume":"42","author":"Tessari","year":"2018","journal-title":"Breast"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"Traversari","year":"1991","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Yang, P., Meng, M., and Zhou, Q. (2021). Oncogenic cancer\/testis antigens are a hallmark of cancer and a sensible target for cancer immunotherapy. Biochim. Biophys. Acta (BBA)-Rev. Cancer, 1876.","DOI":"10.1016\/j.bbcan.2021.188558"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.mpdhp.2011.12.002","article-title":"Characterization of basal-like breast cancer: An update","volume":"18","author":"Bowen","year":"2012","journal-title":"Diagn. Histopathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.acthis.2012.09.006","article-title":"Expression of androgen receptors in triple negative breast carcinomas","volume":"115","year":"2013","journal-title":"Acta Histochem."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Cao, L., and Niu, Y. (2020). Triple negative breast cancer: Special histological types and emerging therapeutic methods. Cancer Biol. Med., 17.","DOI":"10.20892\/j.issn.2095-3941.2019.0465"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.humpath.2021.01.005","article-title":"Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women","volume":"111","author":"Honma","year":"2021","journal-title":"Hum. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7150\/jca.22280","article-title":"The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer","volume":"9","author":"Liao","year":"2018","journal-title":"J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.5114\/aoms.2018.79568","article-title":"Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer","volume":"15","author":"Budzik","year":"2019","journal-title":"Arch. Med. Sci. AMS"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2559.2006.02453.x","article-title":"Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast","volume":"49","author":"Fulford","year":"2006","journal-title":"Histopathology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.22618","article-title":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry","volume":"109","author":"Bauer","year":"2007","journal-title":"Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.breast.2017.06.009","article-title":"Rationale for immunological approaches to breast cancer therapy","volume":"37","author":"Monnot","year":"2018","journal-title":"Breast"},{"key":"ref_48","first-page":"317","article-title":"Relationship between tumor infiltrating lymphocytes and progression in breast cancer","volume":"13","author":"Zgura","year":"2018","journal-title":"Maedica"},{"key":"ref_49","first-page":"1463","article-title":"Phenotypic analysis of tumor infiltrating lymphocytes from human breast cancer","volume":"12","author":"Chin","year":"1992","journal-title":"Anticancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41523-020-0156-0","article-title":"Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer","volume":"6","author":"Kos","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41523-020-0154-2","article-title":"Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group","volume":"6","author":"Amgad","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/bcr3148","article-title":"CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer","volume":"14","author":"Liu","year":"2012","journal-title":"Breast Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Figenschau, S.L., Fismen, S., Fenton, K.A., Fenton, C., and Mortensen, E.S. (2015). Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1116-1"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","article-title":"Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: A systematic review","volume":"2","author":"Stanton","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti\u2013PD-1\/PD-L1 therapy of human cancer: Past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Planes-Laine, G., Rochigneux, P., Bertucci, F., Chretien, A.S., Viens, P., Sabatier, R., and Gon\u00e7alves, A. (2019). PD-1\/PD-L1 targeting in breast cancer: The first clinical evidences are emerging. A literature review. Cancers, 11.","DOI":"10.3390\/cancers11071033"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic Value of Tumor-Infiltrating Lymphocytes (TILs) in Triple Negative Breast Cancers (TNBC) from two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/annonc\/mdv239","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials","volume":"26","author":"Dieci","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2217\/imt-2017-0179","article-title":"Cancer testis antigens as immunogenic and oncogenic targets in breast cancer","volume":"10","author":"Mahmoud","year":"2018","journal-title":"Immunotherapy"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fonc.2020.00050","article-title":"Single tumor cells with epithelial-like morphology are associated with breast cancer metastasis","volume":"10","author":"Tashireva","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/annonc\/mdr038","article-title":"Expression of MAGE-A antigens is frequent in triple-negative breast cancers but does not correlate with that of basal-like markers","volume":"22","author":"Hamai","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1517\/14712598.2010.485188","article-title":"Cancer-germline antigen vaccines and epigenetic enhancers: Future strategies for cancer treatment","volume":"10","author":"Gjerstorff","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"key":"ref_67","unstructured":"Brierly, J.D., Gospodarowicz, M.K., and Wittekind, C. (2017). TNM Classification of Malignant Tumors, John Wiley and Sons. [8th ed.]."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/(SICI)1097-0215(20000215)85:4<460::AID-IJC3>3.0.CO;2-N","article-title":"Expression of MAGE-antigens in normal tissues and cancer","volume":"85","author":"Jungbluth","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J. Natl. Cancer Inst."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/8\/4513\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:31:29Z","timestamp":1760106689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/8\/4513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":71,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["ijms25084513"],"URL":"https:\/\/doi.org\/10.3390\/ijms25084513","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,20]]}}}